Gene delivery to the eye using adeno-associated viral vectors

Keith R G Martin, Ronald L. Klein, Harry A Quigley

Research output: Contribution to journalArticle

Abstract

Adeno-associated virus (AAV) vectors provide a useful way to deliver genes to the eye. They have a number of important properties which make them suitable for this purpose, not least their lack of significant pathogenicity and the potential for long-term transfection of retinal cells. The optimal methods for AAV-mediated gene delivery are determined by the location and characteristics of the target cell type. Efficient gene delivery to photoreceptors and pigment epithelial cells following subretinal injection of AAV has been achieved in various animal models. AAV-mediated gene therapy has been shown to slow photoreceptor loss in rodent models of primary photoreceptor diseases and in dogs with a naturally occurring disease similar to human Leber's congenital amaurosis (LCA). Efficient gene delivery to other cell types such as retinal ganglion cells (RGCs), however, has been more problematic. In this article, we review the potential uses of AAV-mediated gene delivery to the eye. We describe the selection of an appropriate AAV vector for ocular gene transfer studies and discuss the techniques used to deliver the virus to the eye and to assess ocular transfection. We emphasize our techniques for successful gene transfer to retinal ganglion cells, which have often proven challenging to transfect with high efficiency. Using a modified AAV incorporating a chicken β-actin (CBA) promoter and the woodchuck hepatitis posttranscriptional regulatory element, we describe how our techniques allow approximately 85% of rat retinal ganglion cells to be transfected within 2 weeks of a single intravitreal virus injection. Our techniques facilitate the study of the pathogenesis of RGC diseases such as glaucoma and the development of novel new treatments based on gene therapy.

Original languageEnglish (US)
Pages (from-to)267-275
Number of pages9
JournalMethods
Volume28
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Dependovirus
Viruses
Genes
Retinal Ganglion Cells
Gene transfer
Gene therapy
Genetic Therapy
Transfection
Leber Congenital Amaurosis
Marmota
Dog Diseases
Gene Transfer Techniques
Intravitreal Injections
Glaucoma
Hepatitis
Virulence
Actins
Chickens
Rodentia
Animal Models

Keywords

  • Adeno-associated virus
  • Eye
  • Gene therapy
  • Glaucoma
  • Green fluorescent protein
  • Retinal ganglion cell
  • Woodchuck hepatitis posttranscriptional regulatory element

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Gene delivery to the eye using adeno-associated viral vectors. / Martin, Keith R G; Klein, Ronald L.; Quigley, Harry A.

In: Methods, Vol. 28, No. 2, 2002, p. 267-275.

Research output: Contribution to journalArticle

Martin, Keith R G ; Klein, Ronald L. ; Quigley, Harry A. / Gene delivery to the eye using adeno-associated viral vectors. In: Methods. 2002 ; Vol. 28, No. 2. pp. 267-275.
@article{a0bd12a18b5c4779b250b81ac8a19bfb,
title = "Gene delivery to the eye using adeno-associated viral vectors",
abstract = "Adeno-associated virus (AAV) vectors provide a useful way to deliver genes to the eye. They have a number of important properties which make them suitable for this purpose, not least their lack of significant pathogenicity and the potential for long-term transfection of retinal cells. The optimal methods for AAV-mediated gene delivery are determined by the location and characteristics of the target cell type. Efficient gene delivery to photoreceptors and pigment epithelial cells following subretinal injection of AAV has been achieved in various animal models. AAV-mediated gene therapy has been shown to slow photoreceptor loss in rodent models of primary photoreceptor diseases and in dogs with a naturally occurring disease similar to human Leber's congenital amaurosis (LCA). Efficient gene delivery to other cell types such as retinal ganglion cells (RGCs), however, has been more problematic. In this article, we review the potential uses of AAV-mediated gene delivery to the eye. We describe the selection of an appropriate AAV vector for ocular gene transfer studies and discuss the techniques used to deliver the virus to the eye and to assess ocular transfection. We emphasize our techniques for successful gene transfer to retinal ganglion cells, which have often proven challenging to transfect with high efficiency. Using a modified AAV incorporating a chicken β-actin (CBA) promoter and the woodchuck hepatitis posttranscriptional regulatory element, we describe how our techniques allow approximately 85{\%} of rat retinal ganglion cells to be transfected within 2 weeks of a single intravitreal virus injection. Our techniques facilitate the study of the pathogenesis of RGC diseases such as glaucoma and the development of novel new treatments based on gene therapy.",
keywords = "Adeno-associated virus, Eye, Gene therapy, Glaucoma, Green fluorescent protein, Retinal ganglion cell, Woodchuck hepatitis posttranscriptional regulatory element",
author = "Martin, {Keith R G} and Klein, {Ronald L.} and Quigley, {Harry A}",
year = "2002",
doi = "10.1016/S1046-2023(02)00232-3",
language = "English (US)",
volume = "28",
pages = "267--275",
journal = "ImmunoMethods",
issn = "1046-2023",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Gene delivery to the eye using adeno-associated viral vectors

AU - Martin, Keith R G

AU - Klein, Ronald L.

AU - Quigley, Harry A

PY - 2002

Y1 - 2002

N2 - Adeno-associated virus (AAV) vectors provide a useful way to deliver genes to the eye. They have a number of important properties which make them suitable for this purpose, not least their lack of significant pathogenicity and the potential for long-term transfection of retinal cells. The optimal methods for AAV-mediated gene delivery are determined by the location and characteristics of the target cell type. Efficient gene delivery to photoreceptors and pigment epithelial cells following subretinal injection of AAV has been achieved in various animal models. AAV-mediated gene therapy has been shown to slow photoreceptor loss in rodent models of primary photoreceptor diseases and in dogs with a naturally occurring disease similar to human Leber's congenital amaurosis (LCA). Efficient gene delivery to other cell types such as retinal ganglion cells (RGCs), however, has been more problematic. In this article, we review the potential uses of AAV-mediated gene delivery to the eye. We describe the selection of an appropriate AAV vector for ocular gene transfer studies and discuss the techniques used to deliver the virus to the eye and to assess ocular transfection. We emphasize our techniques for successful gene transfer to retinal ganglion cells, which have often proven challenging to transfect with high efficiency. Using a modified AAV incorporating a chicken β-actin (CBA) promoter and the woodchuck hepatitis posttranscriptional regulatory element, we describe how our techniques allow approximately 85% of rat retinal ganglion cells to be transfected within 2 weeks of a single intravitreal virus injection. Our techniques facilitate the study of the pathogenesis of RGC diseases such as glaucoma and the development of novel new treatments based on gene therapy.

AB - Adeno-associated virus (AAV) vectors provide a useful way to deliver genes to the eye. They have a number of important properties which make them suitable for this purpose, not least their lack of significant pathogenicity and the potential for long-term transfection of retinal cells. The optimal methods for AAV-mediated gene delivery are determined by the location and characteristics of the target cell type. Efficient gene delivery to photoreceptors and pigment epithelial cells following subretinal injection of AAV has been achieved in various animal models. AAV-mediated gene therapy has been shown to slow photoreceptor loss in rodent models of primary photoreceptor diseases and in dogs with a naturally occurring disease similar to human Leber's congenital amaurosis (LCA). Efficient gene delivery to other cell types such as retinal ganglion cells (RGCs), however, has been more problematic. In this article, we review the potential uses of AAV-mediated gene delivery to the eye. We describe the selection of an appropriate AAV vector for ocular gene transfer studies and discuss the techniques used to deliver the virus to the eye and to assess ocular transfection. We emphasize our techniques for successful gene transfer to retinal ganglion cells, which have often proven challenging to transfect with high efficiency. Using a modified AAV incorporating a chicken β-actin (CBA) promoter and the woodchuck hepatitis posttranscriptional regulatory element, we describe how our techniques allow approximately 85% of rat retinal ganglion cells to be transfected within 2 weeks of a single intravitreal virus injection. Our techniques facilitate the study of the pathogenesis of RGC diseases such as glaucoma and the development of novel new treatments based on gene therapy.

KW - Adeno-associated virus

KW - Eye

KW - Gene therapy

KW - Glaucoma

KW - Green fluorescent protein

KW - Retinal ganglion cell

KW - Woodchuck hepatitis posttranscriptional regulatory element

UR - http://www.scopus.com/inward/record.url?scp=0036430302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036430302&partnerID=8YFLogxK

U2 - 10.1016/S1046-2023(02)00232-3

DO - 10.1016/S1046-2023(02)00232-3

M3 - Article

VL - 28

SP - 267

EP - 275

JO - ImmunoMethods

JF - ImmunoMethods

SN - 1046-2023

IS - 2

ER -